HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

This study is testing HRYZ-T102, a type of immune cell therapy (TCR-T cell therapy) engineered to recognize and attack cancer cells that produce a protein called AFP, in people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that test positive for AFP. **You may be eligible if...** - You are between 18 and 75 years old - You have a specific genetic marker called HLA-A 02:03 (detectable by blood test) - Your liver cancer or solid tumor has been confirmed AFP-positive by biopsy or blood test (AFP level at or above 400 ng/mL) - Your cancer is advanced stage (BCLC stage B or C for liver cancer) and not suitable for surgery - You have had at least one prior line of systemic treatment - Your physical performance is good (ECOG 0-1) and your liver function is adequate (Child-Pugh score 7 or below) **You may NOT be eligible if...** - You do not have the HLA-A 02:03 genetic marker - You have active autoimmune disease - You have had a prior organ transplant - You are pregnant or breastfeeding - Your organ function does not meet required levels Talk to your doctor to see if this trial is right for you.